Cloridrato de raloxifeno CAS:82640-04-8

Cloridrato de Raloxifeno, um modulador seletivo de receptor de estrogênio de segunda geração (SERM) na família do cloridrato de raloxifeno benzotiofeno. Em setembro 13, 2007, o você. S. A Food and Drug Administration aprovou o Evista para redução do risco de câncer de mama invasivo em mulheres na pós-menopausa com cloridrato de raloxifeno sem osteoporose. Também foi aprovado como um potente tratamento autônomo para osteoporose..

Raloxifene is used to prevent and treat osteoporosis (condition in which the bones become thin and weak and break easily) in women have undergone menopause. Raloxifene is also used to decrease the risk of developing invasive breast cancer (breast cancer that has spread outside of the milk ducts or lobules into the surrounding breast tissue).

Raloxifene prevents and treats osteoporosis by mimicking the effects of estrogen (a female hormone produced by the body) to increase the density (thickness) of bone. Raloxifene decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue. This may stop the development of tumors that need estrogen to grow.